Targeted Charge-Reversal Nanocarriers for Nuclear Drug Delivery

WANG Xing-ping,TANG Jian-bin,SUI Mei-hua,WANG Xin-ping,SHEN You-qing

DOI: https://doi.org/10.14028/j.cnki.1003-3726.2010.12.015

IF: 2.843

2010-01-01

Polymer Bulletin

Abstract:Most anticancer drugs are DNA-toxins eliciting their pharmaceutical effects on nuclear DNA.However,the intrinsic and acquired drug resistance mechanisms of cancer cells efficiently limit their nuclear localization.Most current drug delivery systems target the cytoplasmic organelles,e.g.lysosomes,rather than nuclei.Recently,charge-reversal drug carriers based on β-carboxyl acid amidized cationic polymers,such as PEI and PLL,have been developed to deliver drugs into cancer cell nuclei.The β-carboxyl amidized cationic polymers are negatively charged,which prevents their nonspecific interactions with proteins and cells in the blood,and hence nonspecific uptakes by cells.Once the drug carriers are endocytosed by cancer cells via their targeting groups and enter acidic lysosomes,the β-carboxyl amides hydrolyze rapidly into corresponding amines.As a result,the drug carriers become positively charged again,which enables the drug carriers to escape from the lysosomes and localize in the nuclei.Our results indicate that the charge-reversal drug carriers effectively circumvent the drug resistance of cancer cells,and thus improve the drug efficacy with reduced system toxicity.Herein,the progress and prospective of the targeted charge-reversal carriers for nuclear drug delivery are reviewed.